Although severe hypoglycemia has been reported even with the single usage of SU [31], a meta-analysis of combination therapy efficacy of DPP-4 inhibitors with SU in patients with T2DM showed that the risk of hypoglycemia was increased by approximately 50% [32]. Here, DPP4 is linked to type 2 diabetes mellitus.